Unilife scores with sanofi-aventis
Tuesday, 01 July, 2008
Unilife Medical Solutions [ASX: UNI] has reached an agreement worth over $16 million with sanofi-aventis over licensing rights for Unilife's ready-to-fill syringe [RTFS].
In exchange for the $16.4 million license fee, sanofi-aventis will have exclusive rights to the product for a period of five years.
It is expected that a further agreement will be reached whereby sanofi-aventis will pay the industrialisation costs for the RTFS, which are estimated to total $24-27 million.
Unilife began pilot production of the RTFS units earlier this year, and full commercialisation of the product is expected to begin in 2011.
The RTFS is a pre-filled safety syringe with automatic, user-controlled needle retraction features to help prevent needlestick injuries.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
